LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Medtronic PLC

Fechado

SetorSaúde

87.41 0.59

Visão Geral

Variação de preço das ações

24h

Atual

Mín

87.07

Máximo

87.41

Indicadores-chave

By Trading Economics

Rendimento

16M

1.3B

Vendas

-111M

8.3B

P/E

Médio do Setor

23.197

51.198

EPS

1.62

Rendimento de Dividendos

3.39

Margem de lucro

15.605

Funcionários

95,000

EBITDA

-42M

2.4B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+10.07% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.39%

2.40%

Próximos Ganhos

19 de ago. de 2025

Próxima data de dividendos

11 de jul. de 2025

Próxima data de ex-dividendo

27 de jun. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-13B

107B

Abertura anterior

86.82

Fecho anterior

87.41

Sentimento de Notícias

By Acuity

26%

74%

68 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Medtronic PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

21 de mai. de 2025, 11:38 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

18 de fev. de 2025, 12:24 UTC

Ganhos

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

21 de mai. de 2025, 17:23 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

21 de mai. de 2025, 11:39 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

21 de mai. de 2025, 10:52 UTC

Ganhos

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

21 de mai. de 2025, 10:51 UTC

Ganhos

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

21 de mai. de 2025, 10:50 UTC

Ganhos

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

21 de mai. de 2025, 10:49 UTC

Ganhos

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

21 de mai. de 2025, 10:49 UTC

Ganhos

Medtronic Names Michael Carter Sr VP, President of Cranial, Spinal Technologies >MDT

21 de mai. de 2025, 10:48 UTC

Ganhos

Medtronic Names Skip Kiil Exec VP, President of Cardiovascular Portfolio >MDT

21 de mai. de 2025, 10:48 UTC

Ganhos

Medtronic: Sean Salmon, Exec VP and President of, Cardiovascular Portfolio Leaving >MDT

21 de mai. de 2025, 10:47 UTC

Ganhos

Medtronic Raises Quarterly Dividend to 71c From 70c >MDT

21 de mai. de 2025, 10:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Medtronic: Preferred Path of Initial Public Offering, Subsequent Split-Off >MDT

21 de mai. de 2025, 10:45 UTC

Ganhos

Medtronic Reports Strong Finish To Its Fiscal Year With Its Fourth Quarter Financial Results; Announces Dividend Increase >MDT

21 de mai. de 2025, 10:45 UTC

Ganhos

Medtronic 4Q Net $1.06B >MDT

21 de mai. de 2025, 10:45 UTC

Ganhos

Medtronic 4Q Medical Surgical Portfolio Rev $2.21B >MDT

21 de mai. de 2025, 10:45 UTC

Ganhos

Medtronic 4Q Neuroscience Portfolio Rev $2.62B >MDT

21 de mai. de 2025, 10:45 UTC

Ganhos

Medtronic 4Q Diabetes Rev $728M >MDT

21 de mai. de 2025, 10:45 UTC

Ganhos

Medtronic 4Q Organic Revenue Up 5.4% >MDT

21 de mai. de 2025, 10:45 UTC

Ganhos

Medtronic 4Q Adj EPS $1.62 >MDT

21 de mai. de 2025, 10:45 UTC

Ganhos

Medtronic 4Q EPS 82c >MDT

21 de mai. de 2025, 10:45 UTC

Ganhos

Medtronic 4Q Cardiovascular Portfolio Rev $3.34B >MDT

21 de mai. de 2025, 10:45 UTC

Ganhos

Medtronic 4Q Sales $8.93B >MDT

21 de mai. de 2025, 09:00 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Medtronic to Separate Diabetes Business as Stand-Alone Company -- WSJ

21 de mai. de 2025, 09:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Medtronic to Separate Diabetes Business, Sources Say -- WSJ

21 de mai. de 2025, 09:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Medtronic's Separation of Diabetes Business to Finish Within 18 Months, Sources Say -- WSJ

21 de mai. de 2025, 09:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Medtronic Diabetes Business Sales Totaled Nearly $2.5B in 2024 -- WSJ

27 de fev. de 2025, 10:30 UTC

Principais Notícias

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18 de fev. de 2025, 11:47 UTC

Ganhos

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18 de fev. de 2025, 11:46 UTC

Ganhos

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

Comparação entre Pares

Variação de preço

Medtronic PLC Previsão

Preço-alvo

By TipRanks

10.07% parte superior

Previsão para 12 meses

Média 95.76 USD  10.07%

Máximo 109 USD

Mínimo 87 USD

Com base em 21 analistas de Wall Street que oferecem metas de preço de 12 meses para Medtronic PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

21 ratings

11

Comprar

10

Manter

0

Vender

Pontuação Técnica

By Trading Central

83.26 / 84.875Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

68 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.